CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Constitutive expression of interleukin-27 diminishes proinflammatory cytokine production without impairing effector function of engineered T cells.
Constitutive expression of interleukin-27 diminishes proinflammatory cytokine production without impairing effector function of engineered T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫调节性细胞因子可以改变肿瘤微环境并促进肿瘤清除。IL-27是一种多效性细胞因子，具有增强抗肿瘤免疫的潜力，同时也能促进抗骨髓瘤活性。我们将人类T细胞工程化改造，使其表达重组单链（sc）IL-27以及靶向骨髓瘤抗原B细胞成熟抗原的合成抗原受体，并在体外和体内评估了携带scIL-27的T细胞的抗肿瘤功能。我们发现，携带scIL-27的T细胞维持了抗肿瘤免疫和细胞毒性，但促炎细胞因子粒细胞-巨噬细胞集落刺激因子和肿瘤坏死因子α显著减少。因此，表达IL-27的T细胞由于促炎细胞因子谱减少，为规避通常与工程化T细胞治疗相关的治疗毒性提供了一条潜在途径。
Immunomodulatory cytokines can alter the tumor microenvironment and promote tumor eradication. Interleukin (IL)-27 is a pleiotropic cytokine that has potential to augment anti-tumor immunity while also facilitating anti-myeloma activity.
We engineered human T cells to express a recombinant single-chain (sc)IL-27 and a synthetic antigen receptor targeting the myeloma antigen, B-cell maturation antigen, and evaluated the anti-tumor function of T cells bearing scIL-27 in vitro and in vivo.
We discovered that T cells bearing scIL-27 sustained anti-tumor immunity and cytotoxicity yet manifested a profound reduction in pro-inflammatory cytokines granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha. IL-27-expressing T cells therefore present a potential avenue to avert treatment-related toxicities commonly associated with engineered T-cell therapy due to the reduced pro-inflammatory cytokine profile.
MEMBER ACCOUNT
登录成功会直接打开下一页。
